A novel red grape cells complex: health effects and bioavailability of natural resveratrol

Int J Food Sci Nutr. 2014 Nov;65(7):848-55. doi: 10.3109/09637486.2014.917152. Epub 2014 May 15.

Abstract

In this study, we present a novel product consisted of red grape cells (RGC) grown in culture and evaluated its effect on human LDL oxidation (in vitro) and inflammatory stress (in an in vivo rat model). We analyzed RGC for its polyphenols content and characterized RGC-derived resveratrol (RES) and its properties; and finally, we characterized the pharmacokinetic profile of RGC-RES in human plasma. RGC has demonstrated a strong inhibitory effect on LDL oxidation with IC50 as low as 8.0 μg/ml. RGC significantly reduced rats inflamed paw size induced by carrageenan injection. LC/MS analysis has shown that the main polyphenol in RGC was RES with one hexose moiety. The human pharmacokinetic analysis (clinicaltrials.gov NCT01747252) revealed relatively high bioavailability and two distinctly separated plasma concentration peaks at 1 and 5 h. The present study demonstrates antioxidant and anti-inflammatory traits of RGC that warrants further research in both pre-clinical and clinical settings.

Keywords: Piceid; polyphenols; red grapes; resveratrol.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Biological Availability
  • Carrageenan / toxicity
  • Cross-Over Studies
  • Edema / chemically induced
  • Edema / drug therapy
  • Humans
  • Indomethacin / pharmacology
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Lipoproteins, LDL / chemistry*
  • Lipoproteins, LDL / metabolism
  • Male
  • Oxidation-Reduction
  • Rats
  • Rats, Sprague-Dawley
  • Resveratrol
  • Stilbenes / chemistry
  • Stilbenes / pharmacokinetics
  • Stilbenes / pharmacology*
  • Vitis / classification*
  • Vitis / cytology*

Substances

  • Lipoproteins, LDL
  • Stilbenes
  • Carrageenan
  • Resveratrol
  • Indomethacin

Associated data

  • ClinicalTrials.gov/NCT01747252